Table 3.

Predictors of EFS and OS in Patients with Localized Disease (n=54)

Characteristic	#	5-year EFS (95% CI)	Log-rank Test p value	5-year OS (95% CI)	Log-rank Test p value
Clinical Trial Group
COG	24	61.5% (38.9–77.9)	0.21	69.2% (45.7–84.1)	0.38
EpSSG	30	79.6% (60.1–90.3)		80.6% (58.6–91.7)
Gender
Female	28	61.2% (38.9–77.5)	0.24	68.5% (46.0–83.2)	0.18
Male	26	80.8% (59.8–91.5)		82.2% (58.7–93.1)
Age
1–9 years	18	77.8% (51.1–91.0)	0.62	75.4% (46.4–90.2)	0.97
10–17 years	31	68.9% (48.1–82.7)	0.62	73.7% (51.7–86.8)	0.97
≥ 18 years	5	--		--
FNCLCC Grade
2	24	91.7% (70.6–97.8)	0.01	89.8% (64.3–97.4)	0.02
3	30	54.4% (34.2–70.8)		62.8% (41.2–78.4)
Tumor Invasiveness^
T1	36	86.1% (69.8–94.0)	0.0002	84.1% (65.7–93.2)	0.01
T2	17	34.3% (11.0–59.5)		52.3% (23.4–74.8)
Maximal Tumor Diameter^
≤ 5 cm	37	77.2% (59.2–88.0)	0.09	78.0% (58.8–89.0)	0.21
> 5 cm	16	55.6% (28.6–75.9)		66.6% (37.2–84.7)
Lymph Node Involvement°
No	48	78.2% (63.0–87.7)	0.0002	83.7% (68.5–91.9)	<0.0001
Yes	4	--		--
IRS Group
I	32	86.7% (68.1–94.8)	0.01	89.1% (69.7–96.4)	0.004
II	6	50.0% (11.1-80.4)		66.7% (19.5–90.4)
III	16	48.6% (22.9–70.3)		48.1% (18.8–72.6)
Treatment Response§
PR	10	58.3% (23.0–82.1)	0.68	51.4% (14.3–79.6)	0.93
SD	5	--		--
Site within Extremity*
Distal	31	75.8% (55.3–87.8)	0.77	82.3% (62.3–92.3)	0.69
Proximal	9	88.9% (43.3–98.4)		87.5% (38.7–98.1)

CI: confidence intervals; COG: Children’s Oncology Group; EFS: event-free survival; EpSSG: European paediatric Soft Tissue Sarcoma Group; FNCLCC: Fédération Nationale des Centres de Lutte Contre le Cancer; IRS: Intergroup Rhabdomyosarcoma Study; OS: overall survival; PR: partial response; SD: stable disease

^{^}1 patient with tumor invasiveness and maximal tumor diameter unknown

^°2 patients with loco-regional lymph node status un known

^§1 patient with progressive disease excluded

^*40 patients with extremity tumors